Biodistribution and stability studies of [18F]fluoroethylrhodamine B, a potential PET myocardial perfusion agent
- PMID: 20346876
- PMCID: PMC2847581
- DOI: 10.1016/j.nucmedbio.2009.12.005
Biodistribution and stability studies of [18F]fluoroethylrhodamine B, a potential PET myocardial perfusion agent
Abstract
Introduction: Fluorine-18-labeled rhodamine B was developed as a potential positron emission tomography (PET) tracer for the evaluation of myocardial perfusion, but preliminary studies in mice showed no accumulation in the heart suggesting that it was rapidly hydrolyzed in vivo in mice. A study was therefore undertaken to further evaluate this hypothesis.
Methods: [(18)F]Fluoroethylrhodamine B was equilibrated for 2 h at 37 degrees C in human, rat and mouse serum and in phosphate-buffered saline. Samples were removed periodically and assayed by high-performance liquid chromatography. Based on the results of the stability study, microPET imaging and a biodistribution study were carried out in rats.
Results: In vitro stability studies demonstrated that [(18)F]fluoroethylrhodamine B much more stable in rat and human sera than in mouse serum. After 2 h, the compound was >80% intact in rat serum but <30% intact in mouse serum. The microPET imaging and biodistribution studies in rats confirmed this result showing high and persistent tracer accumulation in the myocardium compared with the absence of uptake by the myocardium in mice thereby validating our original hypothesis that (18)F-labeled rhodamines should accumulate in the heart.
Conclusions: [(18)F]Fluoroethylrhodamine B is more stable in rat and human sera than it is in mouse serum. This improved stability is demonstrated by the high uptake of the tracer in the rat heart in comparison to the absence of visible uptake in the mouse heart. These observations suggest that (18)F-labeled rhodamines are promising candidates for more extensive evaluation as PET tracers for the evaluation of myocardial perfusion.
Copyright 2010 Elsevier Inc. All rights reserved.
Figures





Similar articles
-
(18)F-labeled rhodamines as potential myocardial perfusion agents: comparison of pharmacokinetic properties of several rhodamines.Nucl Med Biol. 2015 Oct;42(10):796-803. doi: 10.1016/j.nucmedbio.2015.06.008. Epub 2015 Jun 18. Nucl Med Biol. 2015. PMID: 26205075 Free PMC article.
-
Research Progress on 18F-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography.Molecules. 2017 Mar 30;22(4):562. doi: 10.3390/molecules22040562. Molecules. 2017. PMID: 28358340 Free PMC article. Review.
-
Effect of the prosthetic group on the pharmacologic properties of 18F-labeled rhodamine B, a potential myocardial perfusion agent for positron emission tomography (PET).J Med Chem. 2012 Dec 27;55(24):11004-12. doi: 10.1021/jm301453p. Epub 2012 Dec 14. J Med Chem. 2012. PMID: 23210516 Free PMC article.
-
Biological characterization of F-18-labeled rhodamine B, a potential positron emission tomography perfusion tracer.Nucl Med Biol. 2013 Nov;40(8):1043-8. doi: 10.1016/j.nucmedbio.2013.07.006. Epub 2013 Sep 4. Nucl Med Biol. 2013. PMID: 24011396 Free PMC article.
-
Synthesis and preliminary evaluation of 18F-labeled pyridaben analogues for myocardial perfusion imaging with PET.J Nucl Med. 2012 Mar;53(3):472-9. doi: 10.2967/jnumed.111.088096. Epub 2012 Feb 2. J Nucl Med. 2012. PMID: 22302832
Cited by
-
(18)F-labeled rhodamines as potential myocardial perfusion agents: comparison of pharmacokinetic properties of several rhodamines.Nucl Med Biol. 2015 Oct;42(10):796-803. doi: 10.1016/j.nucmedbio.2015.06.008. Epub 2015 Jun 18. Nucl Med Biol. 2015. PMID: 26205075 Free PMC article.
-
Peptide-Based Strategies for Targeted Tumor Treatment and Imaging.Pharmaceutics. 2021 Apr 2;13(4):481. doi: 10.3390/pharmaceutics13040481. Pharmaceutics. 2021. PMID: 33918106 Free PMC article. Review.
-
Research Progress on 18F-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography.Molecules. 2017 Mar 30;22(4):562. doi: 10.3390/molecules22040562. Molecules. 2017. PMID: 28358340 Free PMC article. Review.
-
Methods to Increase the Metabolic Stability of (18)F-Radiotracers.Molecules. 2015 Sep 3;20(9):16186-220. doi: 10.3390/molecules200916186. Molecules. 2015. PMID: 26404227 Free PMC article. Review.
-
Mitochondrial-Targeted Molecular Imaging in Cardiac Disease.Biomed Res Int. 2017;2017:5246853. doi: 10.1155/2017/5246853. Epub 2017 May 30. Biomed Res Int. 2017. PMID: 28638829 Free PMC article. Review.
References
-
- Higuchi T, Bengel FM. Cardiovascular nuclear imaging: from perfusion to molecular function. Heart. 2008;94:809–16. - PubMed
-
- Beller GA, Watson DD. A Welcomed New Myocardial Perfusion Imaging Agent for Positron Emission Tomography. Circulation. 2009;119:2299–301. - PubMed
-
- Studenov AR, Berridge MS. Synthesis and properties of 18F-labeled potential myocardial blood flow tracers. Nuc Med Biol. 2001;28:683–93. - PubMed
-
- Ravert HT, Madar I, Dannals RF. Radiosynthesis of 3-[18F]fluoropropyl and 4-[18F]fluorobenzyl triarylphosphonium ions. J Label Compd Radiopharm. 2004;47:469–76.
-
- Madar I, Ravert HT, Du Y, Hilton J, Volokh L, Dannals RF, et al. Characterization of Uptake of the New PET Imaging Compound 18F-Fluorobenzyl Triphenyl Phosphonium in Dog Myocardium. J Nucl Med. 2006;47:1359–66. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources